Interestingly, in 2007, this research group further described a targeted approach to treat pancreatic cancer, in which they developed a versatile expression vector “VISA” operated by pancreatic-cancer-specific promoter (CCKAR-VISA), in which VP16-GAL4-WPRE was integrated with a systemic amplifier and a promoter gene of CCKAR, to target BikDD expression, a potent proapoptotic gene, in pancreatic tumors in vivo.9 The gene discussed is CCKAR; the disease is pancreatic neoplasm.